The historical rank and industry rank for Tissue Regenix Group's PB Ratio or its related term are showing as below:
FRA:LSW'
s PB Ratio Range Over the Past 10 Years
Min: 0.16 Med: 1.27 Max: 2.15
Current: 0.2
During the past 13 years, Tissue Regenix Group's highest PB Ratio was 2.15. The lowest was 0.16. And the median was 1.27.
FRA:LSW's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.8
vs FRA:LSW: 0.20
During the past 12 months, Tissue Regenix Group's average Book Value Per Share Growth Rate was -8.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -2.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -24.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -24.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Tissue Regenix Group was 31.50% per year. The lowest was -51.10% per year. And the median was -6.20% per year.
Back to Basics: PB Ratio
Tissue Regenix Group (FRA:LSW) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Tissue Regenix Group PB Ratio Related Terms
Tissue Regenix Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tissue Regenix Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Tissue Regenix Group (FRA:LSW) has a PB Ratio of 0.20 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tissue Regenix Group and its competitors. This is 84% below median its historical median of 1.27. Over the past decade, Tissue Regenix Group's PB Ratio has ranged from 0.16 to 2.15.
Is Tissue Regenix Group's PB Ratio too high?
Tissue Regenix Group's current PB Ratio of 0.20 is 84% below median its 10-year median of 1.27. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 2.15. The Biotechnology industry median PB Ratio is 2.80. Tissue Regenix Group's value of 0.20 is 92.9% below this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's PB Ratio compare to VRTX and REGN?
Tissue Regenix Group's PB Ratio of 0.20 can be compared against companies in the Biotechnology industry. The industry median PB Ratio is 2.80. Tissue Regenix Group's value of 0.20 is 92.9% below this benchmark. Historically, Tissue Regenix Group's own PB Ratio has ranged from 0.16 to 2.15 over the past decade. While the company's 10-year median is 1.27 vs. the industry median of 2.80, Tissue Regenix Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current PB Ratio of 0.20 is 92.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current PB Ratio is 0.20, which is 84% below median its own 10-year median of 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current PB Ratio of 0.20. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current PB Ratio is 0.20, which is 84% below median its 10-year median of 1.27 and 92.9% below the Biotechnology industry median of 2.80. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current PB Ratio is 0.20 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
PB Ratio: 0.20 (84% below median its 10-year median of 1.27)
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
Industry Position: 92.9% below the Biotechnology median
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
